IFPMA President and Chair of the IFPMA CEO Steering Committee, Chief Executive Officer & Chairman of the Executive Committee, UCB
Jean-Christophe Tellier Jean-Christophe Tellier joined UCB in 2011. He became UCB’s Chief Executive Officer on January 1, 2015 after having successfully led UCB’s BioBrands and Solutions division as Executive Vice President. He is a member of the Board of Directors of UCB.
Jean-Christophe Tellier is an experienced global leader. He was trained as a Medical Doctor and specialized in rheumatology. He has built a distinguished 30+ year career in the biopharmaceutical industry, taking on different global leadership responsibilities in different parts of the world. His patient-centric approach, his passion for science, combined with his strategic and operational skills, have allowed him to significantly contribute to UCB’s success in recent years. Jean-Christophe has led the integration of UCB’s sustainability approach into the company’s strategy. He has also been instrumental in humanizing UCB’s approach towards patients, developing the company’s Patient Value Strategy. For Jean-Christophe “engaging the patient in our vision is the best way for our company to be successful in the long term. Having a holistic view of a patient, of his/her life in his/her environment is essential to ensure effective treatment”. Jean-Christophe also believes that “all healthcare players - physicians, payors, carers, industry and academia - should cooperate even more effectively and become stronger partners sharing a same goal: improving patient care”.
Key positions Prior to UCB, Jean-Christophe held the following positions: 2009 Ipsen: President and General Manager of Ipsen’s North American operations 2008 Macrogenics: Maryland-based public biotechnology company Executive Vice President and Chief Commercial Officer 1989 – 2008 Novartis: CEO of Novartis Pharma France CEO of Novartis Pharma Belgium.
Jean-Christophe is currently IFPMA President and Chair of the IFPMA CEO Steering Committee, Member of the Board of the European Federation of Pharmaceutical Associations (EFPIA) and Vice-Chair